{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:45:10Z","timestamp":1761518710583,"version":"build-2065373602"},"reference-count":18,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2003,4,30]],"date-time":"2003-04-30T00:00:00Z","timestamp":1051660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2003,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The Cancer and Leukemia Group B conducted a Phase II trial to evaluate the efficacy, toxicity, and pharmacokinetics of paclitaxel administered at a maximum dose density for patients with chemotherapy\u2010na\u00efve, advanced\u2010stage non\u2013small cell lung carcinoma (NSCLC).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with Stage IIIB\/IV or recurrent NSCLC, a performance status (PS) score of 0\u20131, and no history of chemotherapy exposure were eligible. Paclitaxel, 150 mg\/m<jats:sup>2<\/jats:sup>, was administered over 3 hours during Weeks 1\u20136 of an 8\u2010week cycle. Doses were modified for ANC &lt; 1500\/\u03bcL or for \u2265 Grade 2 neuropathy on the day of therapy. Treatment continued until toxicity or disease progression. Pharmacokinetics were assessed at Weeks 1, 3, and 5 of Cycle 1.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Thirty\u2010eight patients (median age, 64 years; range, 31\u201381 years) were treated. There were 21 males (PS = 0 for 17). Eleven patients had received previous radiation, 2 had brain metastases, 25 had adenocarcinoma, 23 had Stage IV disease, 6 had StageIIIB disease, and 9 had recurrent disease. Grade 3\u20134 granulocytopenia occurred in 39% of patients. There were no deaths due to toxicity. Grade 2 or 3 neuropathy occurred in 29% and 24% of patients, respectively. Ten (27%) patients had Grade 3 hyperglycemia (glucose concentration &gt; 250 mg\/dL). There were 16 partial responses (42%; 95% confidence interval [CI], 26\u201359%). The median survival period was 12.3 months (95% CI, 7.9\u201319.6%), and the 1\u2010year and 2\u2010year survival rates were 52% (95% CI, 39\u201371%) and 26% (95% CI, 15\u201345%), respectively. Paclitaxel pharmacokinetics were consistent with published values and clearance was not induced. Older age and hyperglycemia were associated with greater neurotoxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Paclitaxel at 150 mg\/m<jats:sup>2<\/jats:sup> per week \u00d7 6 every 8 weeks can be administered safely in the cooperative group setting. These Phase II data are comparable to those associated with combination therapy. The weekly dose\u2010dense schedule may be more active than conventional schedules. Cancer 2003;10:2480\u20136. \u00a9 2003 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.11375<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11375","type":"journal-article","created":{"date-parts":[[2003,4,30]],"date-time":"2003-04-30T22:01:10Z","timestamp":1051740070000},"page":"2480-2486","source":"Crossref","is-referenced-by-count":54,"title":["Weekly, high\u2010dose paclitaxel in advanced lung carcinoma"],"prefix":"10.1002","volume":"97","author":[{"given":"Wallace","family":"Akerley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Herndon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merrill J.","family":"Egorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan P.","family":"Lyss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianne M.","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Marc","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Hollis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Ratain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,4,30]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.384"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.388"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504133321507"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1858"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2654"},{"key":"e_1_2_6_7_2","first-page":"9","article-title":"Cisplatin\/etoposide vs paclitaxel\/cisplatin\/G\u2010CSF vs paclitaxel\/cisplatin in non\u2010small\u2010cell lung cancer","volume":"11","author":"Bonomi P","year":"1997","journal-title":"Oncology (Huntingt)."},{"key":"e_1_2_6_8_2","first-page":"47","article-title":"Taxol\u2010based combination chemotherapy and other in vivo preclinical antitumor studies","volume":"15","author":"Rose W","year":"1993","journal-title":"Monogr Natl Cancer Inst."},{"key":"e_1_2_6_9_2","first-page":"55","article-title":"Phase I\/II trial of weekly paclitaxel in patients with advanced lung cancer","volume":"23","author":"Akerley W","year":"1996","journal-title":"Semin Oncol."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2682"},{"issue":"4","key":"e_1_2_6_11_2","first-page":"S12\u201010","article-title":"Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial","volume":"24","author":"Akerley W","year":"1997","journal-title":"Semin Oncol."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686022"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.14.1077"},{"key":"e_1_2_6_15_2","first-page":"206a","article-title":"Validation of paclitaxel limited sampling strategies","volume":"16","author":"Kearns CM","year":"1997","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.3.638"},{"key":"e_1_2_6_17_2","first-page":"1851","article-title":"Taxol\u2010induced apoptosis and phosphorylation of Bcl\u20102 protein involves c\u2010 Raf\u20101 and represents a novel c\u2010Raf\u20101 signal transduction pathway","volume":"56","author":"Blagosklonny MV","year":"1996","journal-title":"Cancer Res."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1999.14.31"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011954"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11375","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:48:41Z","timestamp":1760284121000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11375"}},"subtitle":["<i>A Phase II study with pharmacokinetics by the Cancer and Leukemia Group B<\/i>"],"short-title":[],"issued":{"date-parts":[[2003,4,30]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,5,15]]}},"alternative-id":["10.1002\/cncr.11375"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11375","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2003,4,30]]}}}